Mayoly Spindler is an independent French family-run pharmaceutical company which has been able to grow for several decades through effective and recognized pharmaceutical products. Its know-how mainly covers gastroenterology, rheumatology, ENT, and dermocosmetics in order to diversify its activities. Mayoly Spindler has more than 700 employees. Their vision is to become a reference company internationally in the field of gastroenterology and dermocosmetics. Forty-five percent of their business is done overseas; and on current projections, excluding external growth, this is expected to grow by 60 percent by 2020. The international sphere is a springboard for growth, focusing on developing sales in key zones; including markets such as China.
Contact
Address: 6 Avenue de l’Europe, 78401 Chatou Cedex, France
Phone:+33 1 34 80 55 55
Web: mayoly-spindler.fr
Thierry Drilhon, president of the Franco-British Chamber of Commerce, talks about Brexit, the pro-industry Macron government and his positive outlook on the future of France and Franco-British cooperation. I…
David Kimelfeld, president of Lyon Métropole, speaks out about his plans for the region in terms of industrial innovation and sustainability, describing how Lyon’s historical roots would represent and enhance…
Jean Monin, general manager of Amgen France, discusses the challenges of bringing products to market in France and what is needed to better promote biosimilars. He also talks about his…
Stewart Cole, president of Institut Pasteur, speaks out about his aspirations as the first foreign president of the institute and the main themes of the new strategic plan. Brexit…
Since 1978, Alban Muller has been a point of reference for natural ingredients in cosmetics, pharma and nutraceuticals. In this interview, Mr. Muller, founder and CEO, explains the strategic role…
Catherine Bourrienne-Bautista, Déléguée générale of the GEMME (L’association Genérique Même Medicament, France’s generics and biosimilars association), provides her take on the state of the generics and biosimilars industry in France.…
Maurice-Pierre Planel, president of the CEPS (Comité économique des produits de santé), details how the French government is unique in the way that they engage in drug pricing and comments…
Oliver Brandicourt, Sanofi’s CEO has kept his promise to steer the company back on the path to growth. This change in fortune comes after the French Pharma giant suffered losses…
As the UK prepares to leave the European Union in March 2019, stakeholders across the European life sciences industry are busy preparing for Brexit’s potential impact on their operations. In…
Thierry Philip, president of Institut Curie, talks about the organization, the effect of cancer on Social Security and the need for a cohesive European plan involving all oncology research institutions…
Ipsen global CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From our…
Dr. Catherine Jessus, Director of the INSB (Institute of Biological Sciences), the largest branch of the CNRS (National Center for Scientific Research) in France, discusses the strengths and weaknesses of…
See our Cookie Privacy Policy Here
